FDA allows troubled Baltimore COVID-19 vaccine factory to resume operations
By Linda A. Johnson
Why CDC recommends wearing masks indoors even if fully vaccinated
The CDC updated guidance on masks, saying on July 27, 2021, that people in areas of high COVID-19 transmission should wear them indoors regardless of vaccination status.
BALTIMORE (AP) - The U.S. Food and Drug Administration is allowing the problem-plagued factory of contract manufacturer Emergent BioSolutions to resume production of COVID-19 vaccine, the company said Thursday.
The Baltimore factory was shut down by the FDA in mid-April due to contamination problems that forced the company to trash the equivalent of tens of millions of doses of vaccine it was making under contract for Johnson & Johnson. The bulk vaccine was contaminated with an ingredient for AstraZeneca’s COVID-19 vaccine, which was being made in the same factory.